Another Look: Shanghai Henlius Shares Hit A Near Five-Year High
Last Tuesday I posted an interview by Forbes China with Jason Zhu, the CEO of Shanghai Henlius Biotech. Zhu said he sees more growth ahead for the drug maker based on a pipeline of cancer and ophthalmologic drugs, as well as expanded international partnerships.
The company has had a good stretch since. Its Hong Kong-trade shares soared by almost 7% on Thursday from a day earlier to HK$55.95, their highest close in nearly five years. They eased back to HK$55.90 on Friday, but have risen 145% in the past year.
This past week, the company announced EU GMP certification for the production lines of two drug candidates, accelerating their market entry prospects there; it also unveiled a new licensing partnership with HanchorBio. On June 27, Henlius's board approved a package of stock options and restricted stock units for Zhu and other key staff.
Hong Kong-traded shares in Shanghai Fosun Pharmaceutical – which owns more than 60% of Shanghai Henlius – have trended upwards along with the Zhu-led company. They closed at HK$17.08 on Friday, compared with HK$15.92 on June 24.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
19 minutes ago
- CNBC
Beijing's tussle with Brussels: China retaliates on EU medical devices
CNBC's Chery Kang and Elaine Yu discuss what China's move to impose reciprocal tariffs on the import of medical devices from the European Union could mean for an upcoming EU-China summit later this month.
Yahoo
24 minutes ago
- Yahoo
Oil Prices Now Aligning More With Fundamentals, Lombard Odier's Woods Says
Oil prices declined after OPEC+ agreed to a bigger-than-expected production increase next month. Lombard Odier Asia CIO John Woods shares his views on the energy markets, telling Bloomberg Television that "oil is now aligning more with fundamentals than any geopolitical premium that might have been built in." Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Nissan Motor eyes $4 billion in bond sales, term sheet shows
By Scott Murdoch SYDNEY (Reuters) -Japan's Nissan Motor is eyeing $4 billion worth of dollar and euro senior unsecured bond issuances, according to term sheet reviewed by Reuters. The car maker is looking at a five-, seven- and 10-year dollar bond deal to raise a minimum of at least $750 million in each tranche. Prospective investors have been told the five-year tranche would have a coupon in the mid-7% area, the seven-year tranche would be in the high 7% area while the longer-dated tranche would be in the low 8% area, the term sheet said. Nissan is also looking at a four and eight-year Euro issuance with a minimum size of 500 million euro ($588.40 million) in each tranche. Pricing guidance has been set at high-5% for the four-year and high-6% for eight-year bond, the term sheet said. Nissan said it also planned a 150 billion yen ($1.04 billion) six-year convertible bond. ($1 = 0.8498 euros) ($1 = 144.7900 yen) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
